Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 1

Status

Active not recruiting 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 4

Interventions

Carboplatin 27pembrolizumab 26Cisplatin 24Paclitaxel 21Nivolumab 19Gemcitabine 16Pemetrexed 14Rituximab 14Ipilimumab 12Cyclophosphamide 11Dexamethasone 11Fluorouracil 10Capecitabine 9Docetaxel 9durvalumab 9trastuzumab deruxtecan 9Lenalidomide 8Oxaliplatin 8atezolizumab 8Doxorubicin 7daratumumab 7osimertinib 7Bortezomib 6Cytarabine 6Leucovorin 6Trastuzumab 6olaparib 6venetoclax 6130-nm albumin-bound paclitaxel 5Ado-Trastuzumab Emtansine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has announcements × amivantamab × 1 year × Clear all
NCT02609776 2026-06-05

CHRYSALIS

Janssen Research & Development, LLC

Phase 1 Active not recruiting
751 enrolled 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04487080 2026-05-08

MARIPOSA

Janssen Research & Development, LLC

Phase 3 Active not recruiting
1,074 enrolled 13 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04538664 2026-05-08

PAPILLON

Janssen Research & Development, LLC

Phase 3 Active not recruiting
308 enrolled 12 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-05-08

MARIPOSA-2

Janssen Research & Development, LLC

Phase 3 Active not recruiting
776 enrolled 13 charts 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡